Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival.

Fink SP, Myeroff LL, Kariv R, Platzer P, Xin B, Mikkola D, Lawrence E, Morris N, Nosrati A, Willson JK, Willis J, Veigl M, Barnholtz-Sloan JS, Wang Z, Markowitz SD.

Oncotarget. 2015 Oct 13;6(31):30500-15. doi: 10.18632/oncotarget.5921.

2.

TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration.

Zhang Y, Desai A, Yang SY, Bae KB, Antczak MI, Fink SP, Tiwari S, Willis JE, Williams NS, Dawson DM, Wald D, Chen WD, Wang Z, Kasturi L, Larusch GA, He L, Cominelli F, Di Martino L, Djuric Z, Milne GL, Chance M, Sanabria J, Dealwis C, Mikkola D, Naidoo J, Wei S, Tai HH, Gerson SL, Ready JM, Posner B, Willson JK, Markowitz SD.

Science. 2015 Jun 12;348(6240):aaa2340. doi: 10.1126/science.aaa2340.

3.

Reply to Ashktorab et al.: Mutational landscape of colon cancers in African Americans.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2853. doi: 10.1073/pnas.1505059112. Epub 2015 May 4. No abstract available.

4.

Novel recurrently mutated genes in African American colon cancers.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1149-54. doi: 10.1073/pnas.1417064112. Epub 2015 Jan 12.

5.

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.

Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N.

Science. 2009 Sep 18;325(5947):1555-9. doi: 10.1126/science.1174229. Epub 2009 Aug 6.

6.

Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.

Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, Lowe JB, Wiesner GL, Parmigiani G, Barnholtz-Sloan J, Dawson DW, Velculescu VE, Kinzler KW, Papadopoulos N, Vogelstein B, Willis J, Gerken TA, Markowitz SD.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12921-5. doi: 10.1073/pnas.0901454106. Epub 2009 Jul 17.

7.

Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.

Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjöblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JK, Nikolskaya T, Nikolsky Y, Kopelovich L, Papadopoulos N, Pennacchio LA, Wang TL, Markowitz SD, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE.

Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16224-9. doi: 10.1073/pnas.0808041105. Epub 2008 Oct 13.

8.

The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.

Kinsella TJ, Seo Y, Willis J, Stellato TA, Siegel CT, Harpp D, Willson JK, Gibbons J, Sanabria JR, Hardacre JM, Schulak JP.

Am J Clin Oncol. 2008 Oct;31(5):446-53. doi: 10.1097/COC.0b013e318168f6c4.

PMID:
18838880
9.

Ugene, a newly identified protein that is commonly overexpressed in cancer and binds uracil DNA glycosylase.

Guo C, Zhang X, Fink SP, Platzer P, Wilson K, Willson JK, Wang Z, Markowitz SD.

Cancer Res. 2008 Aug 1;68(15):6118-26. doi: 10.1158/0008-5472.CAN-08-1259.

10.

The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.

Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K.

Genes Chromosomes Cancer. 2008 Nov;47(11):939-46. doi: 10.1002/gcc.20596.

11.

Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.

Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz AM, Kroh EM, Allen A, Fritz BR, Markowitz SD, Tewari M.

Oncogene. 2008 Jun 19;27(27):3880-8. doi: 10.1038/onc.2008.10. Epub 2008 Feb 11.

PMID:
18264139
12.

Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.

Biswas S, Trobridge P, Romero-Gallo J, Billheimer D, Myeroff LL, Willson JK, Markowitz SD, Grady WM.

Genes Chromosomes Cancer. 2008 Feb;47(2):95-106.

PMID:
17985359
13.

The genomic landscapes of human breast and colorectal cancers.

Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B.

Science. 2007 Nov 16;318(5853):1108-13. Epub 2007 Oct 11.

14.

Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.

Wang J, Kuropatwinski K, Hauser J, Rossi MR, Zhou Y, Conway A, Kan JL, Gibson NW, Willson JK, Cowell JK, Brattain MG.

Mol Cancer Ther. 2007 Mar;6(3):1143-50.

15.

A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.

Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG.

Cancer Res. 2007 Jan 15;67(2):665-73.

16.

The consensus coding sequences of human breast and colorectal cancers.

Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE.

Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.

17.

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.

Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.

Cancer Res. 2006 Jan 1;66(1):404-11.

18.

Colorectal cancer: mutations in a signalling pathway.

Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE.

Nature. 2005 Aug 11;436(7052):792.

PMID:
16094359
19.

Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.

Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD.

J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32.

PMID:
16077070
20.

Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells.

Hu YP, Venkateswarlu S, Sergina N, Howell G, St Clair P, Humphrey LE, Li W, Hauser J, Zborowska E, Willson JK, Brattain MG.

J Biol Chem. 2005 Jul 22;280(29):27383-92. Epub 2005 May 11.

21.

Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia.

Xin B, Platzer P, Fink SP, Reese L, Nosrati A, Willson JK, Wilson K, Markowitz S.

Oncogene. 2005 Jan 20;24(4):724-31.

PMID:
15580307
22.

15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17468-73. Epub 2004 Dec 1.

23.

Mutational analysis of the tyrosine phosphatome in colorectal cancers.

Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE.

Science. 2004 May 21;304(5674):1164-6.

24.

Three classes of genes mutated in colorectal cancers with chromosomal instability.

Wang Z, Cummins JM, Shen D, Cahill DP, Jallepalli PV, Wang TL, Parsons DW, Traverso G, Awad M, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz SD, Goldberg ML, Karess R, Kinzler KW, Vogelstein B, Velculescu VE, Lengauer C.

Cancer Res. 2004 May 1;64(9):2998-3001.

25.

High frequency of mutations of the PIK3CA gene in human cancers.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE.

Science. 2004 Apr 23;304(5670):554. Epub 2004 Mar 11. No abstract available.

26.

ErbB family targeting.

Black JD, Brattain MG, Krishnamurthi SA, Dawson DM, Willson JK.

Curr Opin Investig Drugs. 2003 Dec;4(12):1451-4. Review.

PMID:
14763131
27.

Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine.

Tserng KY, Ingalls ST, Boczko EM, Spiro TP, Li X, Majka S, Gerson SL, Willson JK, Hoppel CL.

J Clin Pharmacol. 2003 Aug;43(8):881-93.

PMID:
12953345
28.

The role of transforming growth factor alpha in determining growth factor independence.

Awwad RA, Sergina N, Yang H, Ziober B, Willson JK, Zborowska E, Humphrey LE, Fan R, Ko TC, Brattain MG, Howell GM.

Cancer Res. 2003 Aug 1;63(15):4731-8.

29.

SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers.

Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8412-7. Epub 2003 Jun 26.

30.

Mutational analysis of the tyrosine kinome in colorectal cancers.

Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE.

Science. 2003 May 9;300(5621):949. No abstract available.

31.

PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer.

Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, Lu S, Nosrati A, Rerko RM, Swinler S, Beard L, Lutterbaugh JD, Willis J, Platzer P, Markowitz S.

Cancer Res. 2003 Apr 1;63(7):1568-75.

32.

TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines.

Fink SP, Mikkola D, Willson JK, Markowitz S.

Oncogene. 2003 Mar 6;22(9):1317-23.

PMID:
12618756
33.

Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.

Hempen PM, Zhang L, Bansal RK, Iacobuzio-Donahue CA, Murphy KM, Maitra A, Vogelstein B, Whitehead RH, Markowitz SD, Willson JK, Yeo CJ, Hruban RH, Kern SE.

Cancer Res. 2003 Mar 1;63(5):994-9.

34.

Focus on colon cancer.

Markowitz SD, Dawson DM, Willis J, Willson JK.

Cancer Cell. 2002 Apr;1(3):233-6. Review. No abstract available.

35.

HLTF gene silencing in human colon cancer.

Moinova HR, Chen WD, Shen L, Smiraglia D, Olechnowicz J, Ravi L, Kasturi L, Myeroff L, Plass C, Parsons R, Minna J, Willson JK, Green SB, Issa JP, Markowitz SD.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4562-7. Epub 2002 Mar 19. Erratum in: Proc Natl Acad Sci U S A 2002 Jun 25;99(13):9081.

36.

Prevalence of somatic alterations in the colorectal cancer cell genome.

Wang TL, Rago C, Silliman N, Ptak J, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3076-80. Epub 2002 Feb 26.

37.

Silence of chromosomal amplifications in colon cancer.

Platzer P, Upender MB, Wilson K, Willis J, Lutterbaugh J, Nosrati A, Willson JK, Mack D, Ried T, Markowitz S.

Cancer Res. 2002 Feb 15;62(4):1134-8.

38.

Chromosomal autonomy of hMLH1 methylation in colon cancer.

Li H, Myeroff L, Kasturi L, Krumroy L, Schwartz S, Willson JK, Stanbridge E, Casey G, Markowitz S.

Oncogene. 2002 Feb 21;21(9):1443-9.

39.

Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells.

Venkateswarlu S, Dawson DM, St Clair P, Gupta A, Willson JK, Brattain MG.

Oncogene. 2002 Jan 3;21(1):78-86.

40.

Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK.

Clin Cancer Res. 2001 Oct;7(10):2971-6.

41.

Differential degradation rates of inactivated alkyltransferase in blood mononuclear cells and tumors of patients after treatment with O(6)-benzylguanine.

Liu L, Spiro TP, Qin X, Majka S, Haaga J, Schupp J, Willson JK, Gerson SL.

Clin Cancer Res. 2001 Aug;7(8):2318-24.

42.
43.

Cause-specific mortality coding. methods in the collaborative ocular melanoma study coms report no. 14.

Moy CS, Albert DM, Diener-West M, McCaffrey LD, Scully RE, Willson JK; Collaborative Ocular Melanoma Study Group, prepared by COMS Mortality Coding Committee.

Control Clin Trials. 2001 Jun;22(3):248-62.

PMID:
11384789
44.

Short mononucleotide repeat sequence variability in mismatch repair-deficient cancers.

Zhang L, Yu J, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B.

Cancer Res. 2001 May 1;61(9):3801-5.

45.

Mechanisms underlying losses of heterozygosity in human colorectal cancers.

Thiagalingam S, Laken S, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B, Lengauer C.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2698-702. Epub 2001 Feb 13.

46.

Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line.

Fink SP, Swinler SE, Lutterbaugh JD, Massagué J, Thiagalingam S, Kinzler KW, Vogelstein B, Willson JK, Markowitz S.

Cancer Res. 2001 Jan 1;61(1):256-60.

47.

Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.

Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S, Gong J, Brattain MG, Willson JK.

Cancer Res. 1999 Sep 15;59(18):4725-31.

48.

O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.

Spiro TP, Gerson SL, Liu L, Majka S, Haaga J, Hoppel CL, Ingalls ST, Pluda JM, Willson JK.

Cancer Res. 1999 May 15;59(10):2402-10.

49.

Control of type II transforming growth factor-beta receptor expression by integrin ligation.

Wang D, Sun L, Zborowska E, Willson JK, Gong J, Verraraghavan J, Brattain MG.

J Biol Chem. 1999 Apr 30;274(18):12840-7.

Supplemental Content

Loading ...
Support Center